Attenuation of malignant phenotypes of breast cancer cells through eIF2α-mediated downregulation of Rac1 signaling

International Journal of Oncology

Volumn 45, Issue 6, 2014, Pages 1980-1988

  Hamamura, Kazunori ^a   Minami, Kazumasa ^b   Tanjung, Nancy ^a   Wan, Qiaoqiao ^a   Koizumi, Masahiko ^c   Matsuura, Nariaki ^b   Na, Sungsoo ^a   Yokota, Hiroki ^a,d  

^a Indiana University Purdue University Indianapolis   (United States)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA UNIVERSITY HOSPITAL   (Japan)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; eIF2 ; Guanabenz; Rac1; Salubrinal

Indexed keywords

CASPASE 3; GUANABENZ ACETATE; INITIATION FACTOR 2ALPHA; MATRIGEL; RAC1 PROTEIN; SALUBRINAL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GUANABENZ; PROGESTERONE RECEPTOR; SMALL INTERFERING RNA; CINNAMIC ACID DERIVATIVE; INITIATION FACTOR 2; THIOUREA;

ADHERENT CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER CELL LINE; CANCER GROWTH; CELL ADHESION; CELL COUNT; CELL GROWTH; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME BLOOD LEVEL; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MTT ASSAY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEPHOSPHORYLATION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; WESTERN BLOTTING; BAGG ALBINO MOUSE; BREAST CANCER; CELLS; OSTEOLYSIS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL MOTION; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; EXPERIMENTAL MAMMARY NEOPLASM; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CINNAMATES; DOSE-RESPONSE RELATIONSHIP, DRUG; EUKARYOTIC INITIATION FACTOR-2; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GUANABENZ; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; RAC1 GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; THIOUREA; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899555002     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2366     Document Type: Article

References (34)

1. Ron D: Translational control in the endoplasmic reticulum stress response. J Clin Invest 110: 1383-1388, 2002.
2. Szegezdi E, Logue SE, Gorman AM and Samali A: Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep 7: 880-885, 2006.
3. Hamamura K and Yokota H: Stress to endoplasmic reticulum of mouse osteoblasts induces apoptosis and transcriptional activation for bone remodeling. FEBS Lett 581: 1769-1774, 2007.
4. Hamamura K, Goldring MB and Yokota H: Involvement of p38 MAPK in regulation of MMP13 mRNA in chondrocytes in response to surviving stress to endoplasmic reticulum. Arch Oral Biol 54: 279-286, 2009.
5. Boyce M, Bryant KF, Jousse C, et al: A selective inhibitor of eIF2α dephosphorylation protects cells from ER stress. Science 307: 935-939, 2005.
6. Liu CL, Li X, Hu GL, et al: Salubrinal protects against tunicamycin and hypoxia induced cardiomyocyte apoptosis via the PERK-eIF2α signaling pathway. J Geriatr Cardiol 9: 258-268, 2012.
7. Drexler HCA: Synergistic apoptosis induction in leukemic cells by the phosphatase inhibitor salubrinal and proteasome inhibitors. PLoS One 4: e4161, 2009.
8. Koizumi M, Tanjung NG, Chen A, et al: Administration of salubrinal enhances radiation induced cell death of SW1353 chondrosarcoma cells. Anticancer Res 32: 3667-3674, 2012.
9. Osborne CK, Zhao H and Fuqua SA: Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol 18: 3172-3186, 2000.
10. De Laurentiis M, Cianniello D, Caputo R, et al: Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treat Rev 36 (Suppl 3): S80-S86, 2010.
11. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U and Harbeck N: Triple-negative breast cancer-current status and future directions. Ann Oncol 20: 1913-1927, 2009.
12. Bosch A, Eroles P, Zaragoza R, Vina JR and Lluch A: Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 36: 206-215, 2010.
13. Foulkes WD, Smith IE and Reis-Filho JS: Triple-negative breast cancer. N Engl J Med 363: 1938-1948, 2010.
14. Prud'homme GJ, Glinka Y, Toulina A, Ace O, Subramaniam V and Jothy S: Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist. PLoS One 5: e13831, 2010.
15. Bouquet F, Pal A, Pilones KA, et al: TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res 17: 6754-6765, 2011.
16. Kaur P, Nagaraja GM, Zheng H, et al: A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease. BMC Cancer 12: 120, 2012.
17. Tsaytler P, Harding HP, Ron D and Bertolotti A: Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis. Science 332: 91-94, 2011.
18. Niknejad N, Gorn-Hondermann I, Ma L, et al: Lovastatin-induced apoptosis is mediated by activating transcription factor 3 and enhanced in combination with salubrinal. Int J Cancer 134: 268-279, 2014.
19. Hamamura K, Furukawa K, Hayashi T, et al: Ganglioside GD3 promotes cell growth and invasion through p130Cas and paxillin in malignant melanoma cells. Proc Natl Acd Sci USA 102: 11041-11046, 2005.
20. Shibuya H, Hamamura K, Hotta H, et al: Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3. Cancer Sci 103: 1656-1664, 2012.
21. Sander EE and Collard JG: Rho-like GTPases: Their role in epithelial cell-cell adhesion and invasion. Eur J Cancer 35: 1302-1308, 1999.
22. Wertheimer E, Gutierrez-Uzquiza A, Rosemblit C, Lopez-Haber C, Sosa MS and Kazanietz MG: Rac signaling in breast cancer: a tale of GEFs and GAPs. Cell Signal 24: 353-362, 2012.
23. Heid I, Lubeseder-Martellato C, Sipos B, et al: Early requirement of Rac1 in a mouse model of pancreatic cancer. Gastroenterology 141: 719-730, 2011.
24. Welch HCE, Coadwell WJ, Ellson CD, Ferguson GJ, Andrews SR, Erdjument-Bromage H, et al: P-Rex1, a Ptdlns (3,4,5)P3- and Gβγ- regulated guanine-nucleotide exchange factor for Rac. Cell 108: 809-821, 2002.
25. Yoshizawa M, Kawauchi T, Sone M, et al: Involvement of a Rac activator, p-Rex1, in neurotrophin-derived signaling and neuronal migration. J Neurosci 25: 4406-4419, 2005.
26. Shim JW, Hamamura K, Chen A, Wan Q, Na S and Yokota H: Rac1 mediates load-driven attenuation of mRNA expression of nerve growth factor beta in cartilage and chondrocytes. J Musculoskelet Neuronal Interact 13: 372-379, 2013.
27. Rosenblatt AE, Garcia MI, Lyons L, et al: Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer. Endocr Relat Cancer 18: 207-219, 2011.
28. Yang Y, Du J, Hu Z, et al: Activation of Rac1-PI3K/Akt is required for epidermal growth factor-induced PAK1 activfation and cell migration in MDA-MB-231 brest cancer cells. J Biomed Res 25: 237-245, 2011.
29. Eckhardt BL, Francis PA, Parker BS and Anderson RL: Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov 11: 479-497, 2012.
30. Van Poznak CH, Temin S, Yee GC, et al: American society of clinical oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in meta static breast cancer. J Clin Oncol 29: 1221-1227, 2011.
31. Lee BL, Higgins MJ and Goss PE: Denosumab and the current status of bone-modifying drugs in breast cancer. Acta Oncol 51: 157-167, 2012.
32. Marx RE: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Sug 61: 1115-1118, 2003.
33. He L, Lee J, Jang JH, et al: Osteoporosis regulation by salubrinal through eIF2α mediated differentiation of osteoclast and osteoblast. Cell Signal 25: 552-560, 2013.
34. Hamamura K, Tanjung N and Yokota H: Suppression of osteoclastogenesis through phosphorylation of eukaryotic translation initiation factor 2 alpha. J Bone Miner Metab 31: 618-628, 2013.